December 7-10, 2019
Orlando, FL, US
The meeting provided a high-grade educational experience with the emphasis on updates in the hottest topics in hematology. We took the opportunity to network with the global community of hematology professionals from every subspecialty.
Nov 20-21, 2019
Phoenix, AZ, US
Multiple laboratory and clinical advances that have been made in the field of interstitial delivery of therapeutics to CNS were addressed. We had the opportunity to present the Company in the exhibit space and share the projects WPD101 & WPD104 with the public. Both projects are co-financed by the European Union from the European Regional Development Fund under the Smart Growth Operational Program 2014-2020, Priority I: Support for conducting R&D works by Medium and Small companies and Microenterprises, Sub-measure 1.1.1. Industrial research projects and Experimental development work projects carried out by companies.
March 13-15, 2019
We were given the opportunity to present assumptions of preclinical research for the WPD101 molecule. The research is planned within the “Development of a new medicine used in the therapy of glioblastoma multiforme” project. The project is co-financed by the European Union from the European Regional Development Fund under the Smart Growth Operational Program 2014-2020, Priority I: Support for conducting R&D works by Medium and Small companies and Microenterprises, Sub-measure 1.1.1. Industrial research projects and Experimental development work projects carried out by companies.
March 23-24, 2018
BioForum Summit 2018
We introduced our company and connected with people from scientific and business areas involved in creating and implementing innovations. We took the opportunity to network on pre-scheduled B2B meetings during the biggest partnering conference in Central Europe for the world’s most innovative leaders in the life science sector.
June 21-23, 2018
Brain Tumors Meeting 2018 - From Biology to Therapy
We had an honour to present our development concept of the new targeted drug WPD001 for treatment of glioblastoma. The event took place in Neurobiology Center, Nencki Institute of Experimental Biology. We were also one of the event’s sponsors. The main advantage of the conference was its high scientific quality, specialized topics focused on basic and clinical research on brain tumor biology and therapy. The lectures on recent advances in pathobiology, immunology, diagnosis, and therapy of brain tumors were given by internationally acknowledged experts. Complex interactions between tumor cells, microenvironment and host immunity were discussed.
Check details: http://braintumorswarsaw.pl/
XI Multidisciplinary Conference on Drug Science
We presented a preclinical development plan for the WPD101 for use in targeted therapy of glioblastoma during the XI Multidisciplinary Conference on Drug Science. The event was organized by the Pharmaceutical Institute in Warsaw. Its main subject was "Science for industry, industry for science".
More info: http://www.mknol.eu